Erin Quirk

2.8k citations

42 papers · 1.8k indexed · 2 hit papers · h-index 19

Co-authors: Andrew Cheng Kirsten White Edwin DeJesus Hal Martin Anthony Mills Joseph M. Custodio Paul E. Sax Joel E. Gallant
Topics: HIV/AIDS drug development and treatment (25 papers)HIV Research and Treatment (23 papers)HIV/AIDS Research and Interventions (16 papers)
Cited by: Virology Infectious Diseases Emergency Medicine
Journals: The Lancet Nature Medicine Clinical Infectious Diseases
Partner nations: United States France United Kingdom

In The Last Decade

Erin Quirk

41 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial

2017 278 citations Paul E. Sax, Anton Pozniak et al. The Lancet profile →
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial

2017 257 citations Joel E. Gallant, Adriano Lazzarin et al. The Lancet profile →

Peers

Countries citing papers authored by Erin Quirk

Since Specialization

Citations

This map shows the geographic impact of Erin Quirk's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Erin Quirk with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Erin Quirk more than expected).

Fields of papers citing papers by Erin Quirk

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Erin Quirk. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Erin Quirk. The network helps show where Erin Quirk may publish in the future.

Co-authorship network of co-authors of Erin Quirk

This figure shows the co-authorship network connecting the top 25 collaborators of Erin Quirk. A scholar is included among the top collaborators of Erin Quirk based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Erin Quirk. Erin Quirk is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	TERN-501 monotherapy and combination therapy with TERN-101 in metabolic dysfunction-associated steatohepatitis: the randomized phase 2a DUET trial 2025 ·Nature Medicine ·Mazen Noureddin,Naim Alkhouri,Eric Lawitz,Kris V. Kowdley,Rohit S. Loomba,Lois K. Lee,Christopher T. Jones,Amnon Schlegel,Tonya Marmon,(unknown),(unknown),Erin Quirk,Stephen A. Harrison	2
2	Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial 2018 ·The Lancet HIV ·Eric S. Daar,Edwin DeJesus,Peter Ruane,Gordon Crofoot,Godson Oguchi,Catherine Creticos,Jürgen K. Rockstroh,Jean‐Michel Molina,Ellen Koenig,Ya-Pei Liu,Joseph M. Custodio,Kristen Andreatta,Hiba Graham,Andrew Cheng,Hal Martin,Erin Quirk	117
3	Repeat testing of low-level HIV-1 RNA 2018 ·AIDS ·Kirsten White,Will Garner,(unknown),Joseph J. Eron,Lijie Zhong,Michael D. Miller,Hal Martin,Andrew Plummer,(unknown),(unknown),James P. Porter,David Piontkowsky,(unknown),Heinz Reiske,Erin Quirk	1
4	Patient-Reported Symptoms Over 48 Weeks Among Participants in Randomized, Double-Blind, Phase III Non-inferiority Trials of Adults with HIV on Co-formulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide versus Co-formulated Abacavir, Dolutegravir, and Lamivudine 2018 ·Patient ·David A. Wohl,Amanda Clarke,Franco Maggiolo,Will Garner,Marianne Laouri,Hal Martin,Erin Quirk	41
5	Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial 2018 ·The Lancet HIV ·Jean‐Michel Molina,Douglas Ward,Indira Brar,Anthony Mills,Hans‐Jürgen Stellbrink,Luís F. López‐Cortés,Peter Ruane,Daniel Podzamczer,Cynthia Brinson,Joseph M. Custodio,Hui Liu,Kristen Andreatta,Hal Martin,Andrew Cheng,Erin Quirk	138
6	Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study 2017 ·The Lancet HIV ·Edwin DeJesus,Moti Ramgopal,Gordon Crofoot,Peter Ruane,Anthony LaMarca,Anthony Mills,Claudia Martorell,(unknown),Hans‐Jürgen Stellbrink,Jean‐Michel Molina,Frank A. Post,Ignacio Valero,Danielle Porter,Ya-Pei Liu,Andrew Cheng,Erin Quirk,Devi SenGupta,Huyen Cao	37
7	Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trialbreakdown → 2017 ·The Lancet ·Paul E. Sax,Anton Pozniak,Marisa Montes,Ellen Koenig,Edwin DeJesus,Hans-Jürgen Stellbrink,Andrea Antinori,Kimberly Workowski,Jihad Slim,Jacques Reynes,Will Garner,Joseph M. Custodio,Kirsten White,Devi SenGupta,Andrew Cheng,Erin Quirk	278
8	Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trialbreakdown → 2017 ·The Lancet ·Joel E. Gallant,Adriano Lazzarin,Anthony Mills,Chloe Orkin,Daniel Podzamczer,Pablo Tebas,Pierre-Marie Girard,Indira Brar,Eric S. Daar,David A. Wohl,Jürgen K. Rockstroh,Xuelian Wei,Joseph M. Custodio,Kirsten White,Hal Martin,Andrew Cheng,Erin Quirk	257
9	P176 Clinical pharmacology of the HIV integrase strand transfer inhibitor bictegravir 2017 ·Sexually Transmitted Infections ·Heather Zhang,Joseph M. Custodio,Xuelian Wei,Hui Wang,(unknown),John Ling,Hal Martin,Erin Quirk,(unknown),Brian P. Kearney	10
10	Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial 2017 ·The Lancet HIV ·Paul E. Sax,Edwin DeJesus,Gordon Crofoot,Douglas Ward,Paul Benson,Robin Dretler,Anthony Mills,Cynthia Brinson,(unknown),Xuelian Wei,Kirsten White,Andrew Cheng,Hal Martin,Erin Quirk	72
11	Safety, efficacy, and pharmacokinetics of a single-tablet regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in treatment-naive, HIV-infected adolescents: a single-arm, open-label trial 2016 ·The Lancet HIV ·Aditya H. Gaur,(unknown),(unknown),Natella Rakhmanina,Mohammed Rassool,Rana Chakraborty,(unknown),Pope Kosalaraksa,Wicharn Luesomboon,Danielle Porter,(unknown),Michael R. Myers,Lillian Ting,Devi SenGupta,Erin Quirk,Martin S. Rhee	32
12	Long-term Efficacy and Safety of Tenofovir Disoproxil Fumarate in HIV-1-infected Adolescents Failing Antiretroviral Therapy 2015 ·The Pediatric Infectious Disease Journal ·Marinella Della Negra,(unknown),(unknown),(unknown),Marcos Tadeu Nolasco da Silva,Kristen Andreatta,Bryan S. Graham,Ya-Pei Liu,Erin Quirk	14
13	P026: Week 24 data from a phase 3 clinical trial of E/C/F/TAF in HIV-positive adolescents 2015 ·Journal of the International AIDS Society ·(unknown),(unknown),Aditya H. Gaur,Wasana Prasitsuebsai,Natella Rakhmanina,(unknown),(unknown),Sean Bennett,Andrew Cheng,(unknown),Erin Quirk	11
14	Characterization of vaniprevir, a hepatitis C virus NS3/4A protease inhibitor, in patients with HCV genotype 1 infection: Safety, antiviral activity, resistance, and pharmacokinetics 2013 ·Antiviral Research ·Eric Lawitz,Mark Sulkowski,Ira M. Jacobson,Walter K. Kraft,Benedict Maliakkal,Mohamed Al‐Ibrahim,Stuart C. Gordon,Paul Y. Kwo,Juergen Rockstroh,(unknown),Michelle Miller,Luzelena Caro,Richard Barnard,Peggy Hwang,Jacqueline Gress,Erin Quirk,Niloufar Mobashery	26
15	Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks 2012 ·The Lancet ·Paul E. Sax,Edwin DeJesus,Anthony Mills,Andrew Zolopa,Calvin Cohen,David A. Wohl,Joel E. Gallant,Hui C. Liu,Lijie Zhong,Kitty Yale,Kirsten White,Brian P. Kearney,Javier Szwarcberg,Erin Quirk,Andrew Cheng	335
16	Safety and Immunogenicity of the MRKAd5 gag HIV Type 1 Vaccine in a Worldwide Phase 1 Study of Healthy Adults 2010 ·AIDS Research and Human Retroviruses ·Ouzama Nicholson,(unknown),James G. Kublin,Xiao Sun,Erin Quirk,(unknown),Glenda Gray,Jean W. Pape,Michael Robertson,Devan V. Mehrotra,Steven G. Self,Katherine Turner,Jorge Sánchez,Punnee Pitisuttithum,Ann Duerr,Sheri Dubey,Lisa Kierstead,Danilo R. Casimiro,(unknown)	16
17	Comparative Cell‐Mediated Immunogenicity of DNA/DNA, DNA/Adenovirus Type 5 (Ad5), or Ad5/Ad5 HIV‐1 Clade BgagVaccine Prime‐Boost Regimens 2009 ·The Journal of Infectious Diseases ·David M. Asmuth,Elizabeth Brown,Mark J. DiNubile,Xiao Sun,Carlos del Rı́o,Clayton Harro,Michael C. Keefer,James G. Kublin,Sheri Dubey,Lisa Kierstead,Danilo R. Casimiro,John W. Shiver,Michael Robertson,Erin Quirk,Devan V. Mehrotra	38
18	HIV Seroconversion without Infection after Receipt of Adenovirus‐Vectored HIV Type 1 Vaccine 2008 ·Clinical Infectious Diseases ·Erin Quirk,Robin Mogg,Deborah D. Brown,Michelle Lally,Devan V. Mehrotra,Mark J. DiNubile,Michael Robertson	15
19	Alterations in thigh subcutaneous adipose tissue gene expression in protease inhibitor-based highly active antiretroviral therapy 2005 ·Metabolism ·Juan D. Chaparro,Dominic N. Reeds,Weidong Wen,(unknown),Samuel Klein,Clay F. Semenkovich,Kyongtae T. Bae,Erin Quirk,William G. Powderly,Kevin E. Yarasheski,Ellen Li	28
20	The Pharmacogenetics of Antiretroviral Therapy: A Review of Studies to Date 2004 ·Clinical Infectious Diseases ·Erin Quirk,Howard L. McLeod,William G. Powderly	19

About Erin Quirk

Erin Quirk is a scholar working on Virology, Infectious Diseases and Emergency Medicine, having authored 42 papers that have together received 1.8k indexed citations. Recurring topics across this work include HIV/AIDS drug development and treatment (25 papers), HIV Research and Treatment (23 papers) and HIV/AIDS Research and Interventions (16 papers). The work is most often cited by research in Virology (1.2k citations), Infectious Diseases (1.6k citations) and Emergency Medicine (605 citations). Erin Quirk has collaborated with scholars based in United States, France and United Kingdom. Frequent co-authors include Andrew Cheng, Kirsten White, Edwin DeJesus, Hal Martin, Anthony Mills, Joseph M. Custodio, Paul E. Sax, Joel E. Gallant, David A. Wohl and Xuelian Wei. Their work appears in journals such as The Lancet, Nature Medicine and Clinical Infectious Diseases.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact